A lower proportion of cases than controls were recent users of NSAIDs, statins, or HRT, or were ever users of neuroleptics.
These associations were only observed after excluding women who were "recent" users of hormone replacement therapy and even then were of marginal, and not independent, significance (p = 0.04 and p = 0.08, respectively).
The results of a separate logistic regression to explore the association between frequency of habitual public transport use and recent use are presented in Additional file 1; frequent habitual users were more likely to have been recent users but inclusion of habitual use in Model 2 nevertheless improved the overall fit compared with Model 1.
Among the subset of women who stopped hormone therapy to join PEPI (that is, recent users), the mean duration since last use of hormone therapy was 6.5 months.
Higher percentages of those reporting better perceived or lower evaluated health were recent users.
A total of 3,427 patients (3.4%) were current bisphosphonates users, 652 (0.7%) were recent users, and 95,964 (95.9%) were nonusers.
Of the 4234 women aged 25 44 years participating in a public health survey, 161 (3.8%) were current SSRI users, 60 (1.4%) were recent users and 223 (5.3%) were former users.
Among these, 3 (1.3%) were current users, 3 (1.3%) were recent users and 11 (4.7%) were former users.
Higher percentages of white women, native born, older, and those with higher education and income were recent users.
At blood collection, cases and controls were postmenopausal, were not recent users of PMH, and had no prior diagnosed cancer (except nonmelanoma skin cancer).
